Evidence map›Paper›PMID 29076378›Full record

ArticleExpert opinion on therapeutic targets2017

KCa1.1 channels as therapeutic targets for rheumatoid arthritis.

Christine Beeton

Abstract read
In one paragraph

Article in Expert opinion on therapeutic targets, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Andrology · 2025
    Review
  3. Article
  4. CaInternational journal of molecular sciences · 2023
    Review
  5. A bioengineered probiotic for the oral delivery of a peptide Kv1.3 channel blocker to treat rheumatoid arthritis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Christine Beetona Department of Molecular Physiology and Biophysics , Baylor College of Medicine , Houston , TX , USA.

Funding

New Peptides for the Treatment of Multiple SclerosisR01NS073712 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI BEETON, CHRISTINE · 2011 to 2015
$1.8M
Potassium channels in myotonic dystrophy type 1R03AR059838 · NIAMS · BAYLOR COLLEGE OF MEDICINE · PI BEETON, CHRISTINE · 2010 to 2012
$224k
NIAMS NIH HHS R03 AR059838NINDS NIH HHS R01 NS073712
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntirheumatic AgentsArthritis, RheumatoidHumansLarge-Conductance Calcium-Activated Potassium Channel alpha SubunitsAntirheumatic AgentsKCNMA1 protein, humanLarge-Conductance Calcium-Activated Potassium Channel alpha SubunitsBK channelosteoarthritisregulatory subunitresident joint cellsrheumatoid arthritissynovial fibroblast

Identifiers

PMID29076378
PMCPMC5676537

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.